Amgen’s AMGN stock has declined 12.1% in the past month. Late last month, Amgen announced the much-awaited 52-week top-line ...

Investors recently learned about undisclosed data from one of Amgen's clinical trials. The new information didn't look ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Shares of Amgen Inc. AMGN inched 0.08% higher to $278.32 Tuesday, on what proved to be an all-around mixed trading session ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

Amgen posted earnings that were better than expected last month. Because Amgen stock has heavy institutional ownership, this ...

Dragged down by negative returns for shares of Amgen and Nike, the Dow Jones Industrial Average is down Monday morning.